Off label study to evaluate the efficacy of HCQ for pre-exposure prophylaxis (PrEP) to
prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 350
participants will be assigned to the group that takes HCQ or the group that opts to not take
the study medication. Participants will be NYULH HCW at high risk for occupational exposure
to SARS-CoV-2. Study timepoints will include screening/enrollment, 30 day, 60 day, and 90 day
visits. Questionnaires, and DBS will be collected in all timepoints.